Page 3 - ஸ்லோன் சிம்ப்சன் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Novartis Pharma AG: Novartis announces iptacopan met Phase II study primary endpoint in rare kidney disease IgA nephropathy (IgAN) 3-7 C3 glomerulopathy Basel, 2 1 - Novartis today announced Phase II primary endpoint data showing investigational iptacopan (LNP023) - a first-in-class, oral, targeted factor B inhibitor - reduced protein in the urine (proteinuria), an increasingly recognized surrogate marker correlating with progression to kidney failure 2, and showed promise in stabilizing kidney function in patients with IgA nephropathy (IgAN) 1. The data were presented at the 58 th ERA-EDTA Congress held virtually from June 5-8, 2021. In the Phase II study (NCT03373461), patients (n=112) with IgAN were randomized to placebo or different doses of iptacopan

Czech republicUnited statesIsabella zinckThomas hungerbuehlerVan praetJonathan barrattSamir shahJamie bennettJulie masowSloan simpsonPhil mcnamaraJohn tsaiJ nephrol renovascUniversity of leicesterHead of global drug developmentNovartis institutes for biomedical research